

UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION

AUG 29 2012

IN RE: PRADAXA (DABIGATRAN ETEXILATE)
PRODUCTS LIABILITY LITIGATION

FILED MDL No. 2385

(SEE ATTACHED SCHEDULE)

AUG 2 9 2012

CLERK, U.S. DISTRICT COURT SOUTHERN DISTRICT OF ILLINOIS EAST ST. LOUIS OFFICE

CONDITIONAL TRANSFER ORDER (CTO -4)

On August 8, 2012, the Panel transferred 13 civil action(s) to the United States District Court for the Southern District of Illinois for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. §1407. See F.Supp.2d (J.P.M.L. 2012). Since that time, 17 additional action(s) have been transferred to the Southern District of Illinois. With the consent of that court, all such actions have been assigned to the Honorable David R Herndon.

It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the Southern District of Illinois and assigned to Judge Herndon.

Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. §1407 to the Southern District of Illinois for the reasons stated in the order of August 8, 2012, and, with the consent of that court, assigned to the Honorable David R Herndon.

This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the Southern District of Illinois. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7—day period, the stay will be continued until further order of the Panel.

Inasmuch as no objection is pending at this time, the stay is lifted.

Aug 29, 2012

CLERK'S OFFICE
UNITED STATES
JUDICIAL PANEL ON
MULTIDISTRICT LITIGATION

FOR THE PANEL:

Jeffery N. Lüthi Clerk of the Panel

SOUTHERN DISTRICT OF ILLINOIS CERTIFIED TRUE COPY

By OW OAL CONCERNS

Date <u>08/29/2012</u>

IN RE: PRADAXA (DABIGATRAN ETEXILATE) PRODUCTS LIABILITY LITIGATION

MDL No. 2385

SCHEDULE CTO-4 - TAG-ALONG ACTIONS

DIST	DIV.	C.A.NO.	CASE CAPTION		
ARKANSAS EASTERN					
ARE	4	12-00507	Summers v. Boehringer Ingelheim Pharmaceuticals Inc et al 12-6003G DKH SCW		
ARKANS	AS WEST	ΓERN			
ARW	2	12-02185	Dalton v. Boehringer, Ingelheim Pharmaceuticals, Inc. 12.60036 0比以 et al		
ARW	3	12-03108	Brooks v. Boehringer, Ingelheim Pharmaceuticals, Inc. 17.6037 DRH/SCW et al		
ARW	4	12-04096	Langdon v. Boehringer, Ingelheim Pharmaceuticals, 12-600380RH SCW Inc. et al		
LOUISIA	NA WEST	ΓERN			
LAW	2	12-02125	Hay v. Boehringer Ingelheim Pharmaceuticals Inc et al 12-60039 OWH SCW		
TENNESS	SEE EAST	ΓERN			
TNE	3	12-00419	Zydel v. Boehringer Ingelheim Pharmaceuticals, Inc. ኒշ. ৮০০৭০ እሂደ (Տሮህ et al		
TNE	3	12-00420	Marino v. Boehringer Ingelheim Pharmaceuticals, Inc. 12-60041 ORH SCW et al		
TENNESSEE WESTERN					
TNW	1	12-01177	Lunsford v. Boehringer Ingelheim Pharmaceuticals, 12.60042 DRH SCW Inc. et al		
TEXAS E	ASTERN				
TXE	6	12-00497	Kee v. Boehringer Ingelheim Pharmaceuticals, Inc. et 12-60043 DKH (SCW al		
TXE	6	12-00498	Runte v. Boehringer Ingelheim Pharmaceuticals, Inc. 12.60044 DKH CW et al		
TXE	9	12-00125	Kerr v. Boehringer Ingelheim Pharmaceuticals, Inc. et 12.60045 NR 450W		

TEXAS NORTHERN

TXN	2	12-00166	Jordan v. Boehringer Ingelheim Pharmaceuticals, Inc. 12.60046 DRH/SCW et al		
TXN	4	12-00555	Landers v. Boehringer Ingelheim Pharmaceuticals, \2.60047 DKH SCW Inc. et al		
TXN	4	12-00557	Parry v. Boehringer Ingelheim Pharmaceuticals, Inc. et 12-60048 024 SCW		
TXN	6	12-00053	Self v. Boehringer Ingelheim Pharmaceuticals, Inc. et 12.60049 DKH SCW		
TEXAS SOUTHERN					
TXS	4	12-02381	Cannon v. Boehringer Ingelheim Pharmaceuticals, Inc. 17. 10050 DKH SCW et al		
TXS	4	12-02427	Halford v. Boehringer Ingelheim Pharmaceuticals, Inc. 12-60051 DKH/SCW et al		
TEXAS WESTERN					
TXW	1	12-00715	Whitehouse v. Boehringer Ingelheim Pharmaceuticals, 12-20052 OFH SCW		
TXW	1	12-00716	Conti v. Boehringer Ingelheim Pharmaceuticals, Inc. et 12.6063 DRH SW		